Crawford S M, Parker D, Glaser M G, Southcott B M, Begent R H, Rustin G J, Newlands E S, Ward A J, Bagshawe K D
Cancer Research Campaign Laboratories, Charing Cross Hospital, London, U.K.
Med Oncol Tumor Pharmacother. 1989;6(4):279-83. doi: 10.1007/BF02985162.
Eighty-two patients with small cell lung cancer (SCLC), 32 with limited disease, were treated with alternating chemotherapy. Eight courses were administered at weekly intervals, and responding patients received radiotherapy to sites of bulk disease. Overall response rate was 76.8%. Overall median survival was 265 days, 408 days in patients with limited disease. The median symptom free period after chemotherapy was completed was 123 days. These results are comparable with those in reports of chemotherapy of longer duration and warrant the further investigation of short duration treatment in this disease.
82例小细胞肺癌（SCLC）患者，其中32例为局限期，接受了交替化疗。每隔一周进行8个疗程，有反应的患者对大块病灶部位进行放疗。总缓解率为76.8%。总中位生存期为265天，局限期患者为408天。化疗完成后的中位无症状期为123天。这些结果与疗程较长的化疗报告结果相当，值得对该疾病的短疗程治疗进行进一步研究。
